Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

NCT00490529 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Mantle-Cell

Interventions

BIOLOGICAL: CpG-MCL vaccine
BIOLOGICAL: PF-3512676
PROCEDURE: Vaccine-primed T-cells
PROCEDURE: Autologous hematopoietic stem cell transplant (HSCT)
DRUG: Rituximab
DRUG: Standard induction chemotherapy
DRUG: Cyclophosphamide
DRUG: Filgrastim

Sponsor

Ronald Levy

Collaborators

[object Object]